Advanced computing and shifting economic models are fundamentally reshaping pharmaceutical drug discovery and distribution. Dave Ricks, CEO of Eli Lilly, details the deployment of the industry’s largest biologically focused supercomputer to engineer molecules that obey organic chemistry while bypassing natural limitations. Beyond technical innovation, the expansion of GLP-1 medicines into cardiovascular, renal, and neurodegenerative treatments highlights a shift toward addressing systemic inflammation. However, clinical trials remain a multi-billion dollar bottleneck, with enrollment costs reaching $40,000 per participant. To counter these inefficiencies and opaque pricing structures, Lilly is implementing direct-to-patient distribution via Lilly Direct and advocating for a "one fair price" model to eliminate rebate-driven market distortions. Sustaining this progress requires balancing aggressive R&D—which at Lilly rivals the medical research spending of entire nations—with policy reforms that protect data exclusivity and incentivize domestic manufacturing resilience against global competition.
Sign in to continue reading, translating and more.
Continue
